Skip to content

GSI Cardiac on Revolution Apex - US

Wide Coverage GSI Cardiac Data Collection

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06702917
Enrollment
50
Registered
2024-11-25
Start date
2025-09-10
Completion date
2026-09-01
Last updated
2026-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Catheterization, Coronary Computed Tomographic Angiography, Myocardial Infarction (MI)

Brief summary

The goal of this clinical data collection study is to collect raw CT scan data using a new GSI Cardiac mode on GE HealthCare's Revolution Apex CT system. Two groups of participants will be enrolled: A) Participants scheduled to undergo a Coronary CT Angiography (CCTA) as part of their standard of care B) Participants scheduled to undergo a cardiac catheterization or have a history of heart attack Participants in Group A will: -Have a standard of care CCTA immediately followed by a research GSI Cardiac scan Participants in Group B will: -Have a research CCTA immediately followed by a research GSI Cardiac scan Both groups will be in the study for approximately 1 day. There are no follow-up visits after the day of scan.

Interventions

DEVICEGSI Cardiac Scan

The investigational GSI Cardiac scan will take place immediately ("back-to-back acquisition") following the single energy, non-GSI CCTA. The GSI Cardiac scan takes around 1 minute. A subset of Cohort B's participants who are eligible due to a history of heart attack will have the investigational GSI Cardiac scan 10-15 minutes after the end of the CCTA scan.

OTHERStandard of Care CCTA

The standard of care scan will be a single-energy, non-GSI CCTA. Any pre-contrast screening (such as kidney function or pregnancy testing) will follow the site's standard operating procedures. The administration of contrast media (either IV or oral) and any cardiac medications used to control heart rate will be prescribed per the site's standard operating procedures. All contrast and cardiac medications will be FDA approved and used in accordance with its approval.

OTHERResearch CCTA

The research scan will be a single-energy, non-GSI CCTA. Any pre-contrast screening (such as kidney function or pregnancy testing) will follow the site's standard operating procedures. The administration of contrast media (either IV or oral) and any cardiac medications used to control heart rate will be prescribed per the site's standard operating procedures. All contrast and cardiac medications will be FDA approved and used in accordance with its approval.

Sponsors

GE Healthcare
Lead SponsorINDUSTRY
University of Washington
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Subjects may be included in this study if they meet the following criteria: 1. Who are ≥18 years of age; 2. Able to sign and date the informed consent form; AND, 3. Cohort A: Undergoing a scheduled clinically indicated CCTA; OR, 4. Cohort B: Known history of myocardial infarction or undergoing a clinically indicated cardiac catheterization due to known pathology.

Exclusion criteria

Subjects may be excluded from participating in study if they meet any of the following criteria: 1. Who are pregnant or lactating; 2. Who were previously enrolled in this study; 3. Anyone with known or suspected allergy to iodinated contrast agents; 4. Anyone with known or suspected renal insufficiency as determined by site medical personnel; 5. Who are in need of urgent or emergent care; 6. Who have any conditions that, in the opinion of the PI or designee, would interfere with the evaluation of the results or constitute a health hazard for the subject; 7. Who are unwilling to have GEHC personnel present for the CT exam; AND, 8. Cohort A: Undergoing a scheduled clinically indicated CCTA for anatomy assessment (aberrant origin, etc.)

Design outcomes

Primary

MeasureTime frameDescription
Evaluable GSI Cardiac Raw Scans12 monthsNumber of participants whose GSI Cardiac scan is deemed evaluable (i.e., no issues with participant motion or contrast administration and/or timing).

Secondary

MeasureTime frameDescription
Safety Assessment12 monthsNumber of Adverse Events and/or Serious Adverse Events reported.

Countries

United States

Contacts

STUDY_DIRECTORBrian Thomsen

GE Healthcare

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 16, 2026